Oncolytic Vaccinia virus and radiotherapy in head and neck cancer

D. Mansfield, T. Pencavel, J. N. Kyula, S. Zaidi, V. Roulstone, K. Thway, L. Karapanagiotou, A. A. Khan, M. McLaughlin, Y. Touchefeu, R. Seth, A. A. Melcher, Richard Geoffrey Vile, H. S. Pandha, K. J. Harrington

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: Oncolytic forms of attenuated Vaccinia virus are now in clinical development, assessing the compatibility of this novel treatment with radiotherapy may reveal exploitable synergistic relationships. Materials and methods: In vitro analyses of cell killing, cell cycle effects and caspase activation were carried out on HN3, HN5, CAL27, Detroit, SIHN5B, and PJ41 cells. In vivo studies of the virus and X-radiation were performed on H&N xenografts in CD1 nude mice. Results: Cell killing in vitro was demonstrated to be dose- and time-dependent. Infection causes an increase in S-phase and sub-G1 cells. A dose dependent increase in active caspase-3 indicated induction of apoptosis. Xenografts injected with Vaccinia stabilised and frequently completely regressed. Combination with radiation generated additional cell death, induction of caspase activity and in vivo further improved long term regression rates. Conclusions: These data support continued exploration of this therapy combination and indicates potential for clinical trials in head and neck cancer.

Original languageEnglish (US)
Pages (from-to)108-118
Number of pages11
JournalOral Oncology
Volume49
Issue number2
DOIs
StatePublished - Feb 2013

Fingerprint

Oncolytic Viruses
Vaccinia virus
Head and Neck Neoplasms
Radiotherapy
Caspases
Heterografts
Vaccinia
S Phase
Nude Mice
Caspase 3
Cell Cycle
Cell Death
X-Rays
Clinical Trials
Radiation
Apoptosis
Viruses
Therapeutics
Infection
In Vitro Techniques

Keywords

  • GLV-1h68
  • Head and neck cancer
  • Oncolytic
  • Radiation
  • Vaccinia virus

ASJC Scopus subject areas

  • Oncology
  • Oral Surgery
  • Cancer Research

Cite this

Mansfield, D., Pencavel, T., Kyula, J. N., Zaidi, S., Roulstone, V., Thway, K., ... Harrington, K. J. (2013). Oncolytic Vaccinia virus and radiotherapy in head and neck cancer. Oral Oncology, 49(2), 108-118. https://doi.org/10.1016/j.oraloncology.2012.07.019

Oncolytic Vaccinia virus and radiotherapy in head and neck cancer. / Mansfield, D.; Pencavel, T.; Kyula, J. N.; Zaidi, S.; Roulstone, V.; Thway, K.; Karapanagiotou, L.; Khan, A. A.; McLaughlin, M.; Touchefeu, Y.; Seth, R.; Melcher, A. A.; Vile, Richard Geoffrey; Pandha, H. S.; Harrington, K. J.

In: Oral Oncology, Vol. 49, No. 2, 02.2013, p. 108-118.

Research output: Contribution to journalArticle

Mansfield, D, Pencavel, T, Kyula, JN, Zaidi, S, Roulstone, V, Thway, K, Karapanagiotou, L, Khan, AA, McLaughlin, M, Touchefeu, Y, Seth, R, Melcher, AA, Vile, RG, Pandha, HS & Harrington, KJ 2013, 'Oncolytic Vaccinia virus and radiotherapy in head and neck cancer', Oral Oncology, vol. 49, no. 2, pp. 108-118. https://doi.org/10.1016/j.oraloncology.2012.07.019
Mansfield D, Pencavel T, Kyula JN, Zaidi S, Roulstone V, Thway K et al. Oncolytic Vaccinia virus and radiotherapy in head and neck cancer. Oral Oncology. 2013 Feb;49(2):108-118. https://doi.org/10.1016/j.oraloncology.2012.07.019
Mansfield, D. ; Pencavel, T. ; Kyula, J. N. ; Zaidi, S. ; Roulstone, V. ; Thway, K. ; Karapanagiotou, L. ; Khan, A. A. ; McLaughlin, M. ; Touchefeu, Y. ; Seth, R. ; Melcher, A. A. ; Vile, Richard Geoffrey ; Pandha, H. S. ; Harrington, K. J. / Oncolytic Vaccinia virus and radiotherapy in head and neck cancer. In: Oral Oncology. 2013 ; Vol. 49, No. 2. pp. 108-118.
@article{42826cc890944bb9aa249a3f21ce3695,
title = "Oncolytic Vaccinia virus and radiotherapy in head and neck cancer",
abstract = "Objective: Oncolytic forms of attenuated Vaccinia virus are now in clinical development, assessing the compatibility of this novel treatment with radiotherapy may reveal exploitable synergistic relationships. Materials and methods: In vitro analyses of cell killing, cell cycle effects and caspase activation were carried out on HN3, HN5, CAL27, Detroit, SIHN5B, and PJ41 cells. In vivo studies of the virus and X-radiation were performed on H&N xenografts in CD1 nude mice. Results: Cell killing in vitro was demonstrated to be dose- and time-dependent. Infection causes an increase in S-phase and sub-G1 cells. A dose dependent increase in active caspase-3 indicated induction of apoptosis. Xenografts injected with Vaccinia stabilised and frequently completely regressed. Combination with radiation generated additional cell death, induction of caspase activity and in vivo further improved long term regression rates. Conclusions: These data support continued exploration of this therapy combination and indicates potential for clinical trials in head and neck cancer.",
keywords = "GLV-1h68, Head and neck cancer, Oncolytic, Radiation, Vaccinia virus",
author = "D. Mansfield and T. Pencavel and Kyula, {J. N.} and S. Zaidi and V. Roulstone and K. Thway and L. Karapanagiotou and Khan, {A. A.} and M. McLaughlin and Y. Touchefeu and R. Seth and Melcher, {A. A.} and Vile, {Richard Geoffrey} and Pandha, {H. S.} and Harrington, {K. J.}",
year = "2013",
month = "2",
doi = "10.1016/j.oraloncology.2012.07.019",
language = "English (US)",
volume = "49",
pages = "108--118",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Oncolytic Vaccinia virus and radiotherapy in head and neck cancer

AU - Mansfield, D.

AU - Pencavel, T.

AU - Kyula, J. N.

AU - Zaidi, S.

AU - Roulstone, V.

AU - Thway, K.

AU - Karapanagiotou, L.

AU - Khan, A. A.

AU - McLaughlin, M.

AU - Touchefeu, Y.

AU - Seth, R.

AU - Melcher, A. A.

AU - Vile, Richard Geoffrey

AU - Pandha, H. S.

AU - Harrington, K. J.

PY - 2013/2

Y1 - 2013/2

N2 - Objective: Oncolytic forms of attenuated Vaccinia virus are now in clinical development, assessing the compatibility of this novel treatment with radiotherapy may reveal exploitable synergistic relationships. Materials and methods: In vitro analyses of cell killing, cell cycle effects and caspase activation were carried out on HN3, HN5, CAL27, Detroit, SIHN5B, and PJ41 cells. In vivo studies of the virus and X-radiation were performed on H&N xenografts in CD1 nude mice. Results: Cell killing in vitro was demonstrated to be dose- and time-dependent. Infection causes an increase in S-phase and sub-G1 cells. A dose dependent increase in active caspase-3 indicated induction of apoptosis. Xenografts injected with Vaccinia stabilised and frequently completely regressed. Combination with radiation generated additional cell death, induction of caspase activity and in vivo further improved long term regression rates. Conclusions: These data support continued exploration of this therapy combination and indicates potential for clinical trials in head and neck cancer.

AB - Objective: Oncolytic forms of attenuated Vaccinia virus are now in clinical development, assessing the compatibility of this novel treatment with radiotherapy may reveal exploitable synergistic relationships. Materials and methods: In vitro analyses of cell killing, cell cycle effects and caspase activation were carried out on HN3, HN5, CAL27, Detroit, SIHN5B, and PJ41 cells. In vivo studies of the virus and X-radiation were performed on H&N xenografts in CD1 nude mice. Results: Cell killing in vitro was demonstrated to be dose- and time-dependent. Infection causes an increase in S-phase and sub-G1 cells. A dose dependent increase in active caspase-3 indicated induction of apoptosis. Xenografts injected with Vaccinia stabilised and frequently completely regressed. Combination with radiation generated additional cell death, induction of caspase activity and in vivo further improved long term regression rates. Conclusions: These data support continued exploration of this therapy combination and indicates potential for clinical trials in head and neck cancer.

KW - GLV-1h68

KW - Head and neck cancer

KW - Oncolytic

KW - Radiation

KW - Vaccinia virus

UR - http://www.scopus.com/inward/record.url?scp=84872305052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872305052&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2012.07.019

DO - 10.1016/j.oraloncology.2012.07.019

M3 - Article

C2 - 22925693

AN - SCOPUS:84872305052

VL - 49

SP - 108

EP - 118

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

IS - 2

ER -